UNSPSC 51343825: Glecaprevir/Pibrentasvir

Glecaprevir/pibrentasvir (G/P)is a fixed-dose combination medication used to treat hepatitis C.

UNSPSC 51343825 Glecaprevir/Pibrentasvir, a Commodity code, does not reflect meaningful recent state and local procurement activity. The code identifies a specific antiviral pharmaceutical product used in hepatitis C treatment; however, the recent opportunities dataset shows no active solicitations for this drug or its therapeutic class from state or local governments. Instead, the tagged opportunities span forensic drug reference standards (Pinellas County), emergency medical supplies and naloxone (Seminole County and Tucson), peer support services for mental health workers (San Mateo County), and various vendor networking and informational forums unrelated to pharmaceutical procurement. None of these solicitations require glecaprevir/pibrentasvir or direct-acting antiviral agents for hepatitis C.

The mismatch between the code designation and actual buying patterns suggests either a data labeling error or extremely limited state and local demand for this particular antiviral compound through traditional procurement channels. State and local healthcare purchasing for specialty pharmaceuticals like glecaprevir/pibrentasvir typically flows through Medicaid managed care organizations, pharmacy benefit managers, or centralized state health agencies rather than through open competitive solicitations tagged in this dataset. Until recent opportunities explicitly name this drug or antiviral hepatitis C therapies as line items in a posted RFP, RFQ, IFB, or ITB, the code does not signal actionable procurement activity for business development purposes.